Envoy Medical Inc (COCH) FinancialsCOCHFinancialEnvoy Medical Inc

Evaluating the bottom line, Envoy Medical Inc maintains a gross margin of -445.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10919.61%, while the net margin is -11729.41%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively COCH converts its operational activities into shareholder value.

In the context of the broader market, COCH competes directly with industry leaders such as XTNT and NTRB. With a market capitalization of $56.42M, it holds a significant position in the sector. When comparing efficiency, COCH's gross margin of -445.10% stands against XTNT's 57.88% and NTRB's 45.41%. Such benchmarking helps identify whether Envoy Medical Inc is trading at a premium or discount relative to its financial performance.

Envoy Medical's total revenue for Q2 2026 was $51,000, but it reported a net income loss of -$7,272,000, reflecting ongoing financial struggles. The gross margin is alarmingly negative at -445.10% for the same quarter, indicating severe profitability issues.